Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Pfizer Pharmanet Development Group |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00809354 |
The purpose of this study is to investigate the long-term analgesic efficacy and safety of tanezumab for patients with osteoarthritis (OA) of the knee or hip currently experiencing partial benefit from, and are tolerating, non-steroidal anti-inflammatory drug (NSAID) therapy.
Condition | Intervention | Phase |
---|---|---|
Osteoarthritis Arthritis |
Drug: NSAID Biological: tanezumab |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Phase 3, Multi-Center, Randomized, Double-Blind, Controlled Study Of The Long-Term Analgesic Efficacy And Safety of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip |
Estimated Enrollment: | 2500 |
Study Start Date: | February 2009 |
Estimated Study Completion Date: | November 2010 |
Estimated Primary Completion Date: | April 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
IV Placebo + NSAID: Active Comparator
Oral NSAID
|
Drug: NSAID
IV doses of placebo (to match tanezumab) every 8 weeks (through Week 48) plus oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
|
Tanezumab 5 mg: Experimental
IV tanezumab 5 mg every 8 weeks (through Week 48)
|
Biological: tanezumab
IV tanezumab 5 mg every 8 weeks (through Week 48) and oral placebo for NSAID BID from Weeks 2 through 56
|
Tanezumab 10 mg: Experimental
IV tanezumab 10 mg every 8 weeks (through Week 48)
|
Biological: tanezumab
IV tanezumab 10 mg every 8 weeks (through Week 56) and oral placebo for NSAID BID from Weeks 2 through 56
|
Tanezumab 5 mg + NSAID: Experimental
IV doses of tanezumab 5 mg every 8 weeks (through Week 48) plus oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
|
Biological: tanezumab
IV tanezumab 5 mg every 8 weeks (through Week 48)
Drug: NSAID
Oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
|
Tanezumab 10 mg + NSAID: Experimental
IV doses of tanezumab 10 mg every 8 weeks (through Week 48) plus oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
|
Biological: tanezumab
IV tanezumab 10 mg every 8 weeks (through Week 48)
Drug: NSAID
Oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Pfizer, Inc. ( Director, Clinical Trial Disclosure Group ) |
Study ID Numbers: | A4091025 |
Study First Received: | December 16, 2008 |
Last Updated: | January 13, 2009 |
ClinicalTrials.gov Identifier: | NCT00809354 |
Health Authority: | United States: Food and Drug Administration |
monoclonal antibody, nerve growth factor (NGF), anti-NGF, tanezumab, PF-04383119, RN624, osteoarthritis (OA) |
Antibodies, Monoclonal Osteoarthritis, Knee Antibodies Naproxen Celecoxib Musculoskeletal Diseases |
Osteoarthritis Joint Diseases Arthritis Rheumatic Diseases Immunoglobulins |